DBV demonstrates ability of VIASKIN® to administer allergen via intact skin by targeting dendritic cells for safe treatment of allergic disease
Download official press release (294.3 KB)
By showing all the steps of the passage of an allergen through the intact skin, this study gives the keys of the Treg-oriented mechanism of the safest method of specific immunotherapy in food allergy. Data published in Journal of Immunology by V. Dioszeghy, PhD, and the DBV research team.
“With this study we have now demonstrated the different immunological steps involved and have confirmed the safety of our VIASKIN® method of food allergy desensitization. Clinical trials of VIASKIN® Peanut Epicutaneous Immunotherapy have already begun. VIASKIN® represents the perfect answer to the question of antigen delivery – simple, supremely versatile and pain-free.” Pierre-Henri Benhamou, M.D., CEO.
